Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,850 employees. Alkermes has a diversified commercial product portfolio and a substantial clinical pipeline of central nervous system (CNS) product candidates. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Health Council.
Shane Cooke oversees corporate finance, commercial, business development, corporate planning, quality and manufacturing operations. Mr. Cooke joined Alkermes as President upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Previously, Mr. Cooke was Head of EDT and Executive Vice President of Elan from 2007 through the merger in 2011 and concurrently served as Chief Financial Officer of Elan Corporation from 2001 to May 2011. Mr. Cooke was appointed Director of Elan in May 2005. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company of which he was a founder. Mr. Cooke also previously held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke currently serves on the Board of Directors of Endo International plc and on the Board of Directors of Prothena Biosciences and Prothena Therapeutics, both subsidiaries of Prothena Corporation plc. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland.
Kathy Biberstein oversees compliance, intellectual property, legal, policy, information technology, human resources and operations at the Waltham site. She also has responsibility for enterprise risk management. Ms. Biberstein held several senior legal positions prior to joining Alkermes in 2003, including General Counsel and member of the Executive Committee at Serono in Geneva, Switzerland from 1993 to 2000, where she built a worldwide legal department. Just prior to joining Alkermes, Ms. Biberstein was Of Counsel at Crowell & Moring LLC, and earlier in her career, Ms. Biberstein was a member of the Executive Board of the World Economic Forum. Ms. Biberstein received a Bachelor of Science degree from Kettering University and a Juris Doctor from the University of Michigan Law School.
Iain Brown is responsible for Alkermes’ accounting and financial reporting systems, as well as its tax, treasury, financial planning and analysis, and insurance functions. Mr. Brown has more than 20 years of experience in the biopharmaceutical industry. He joined Alkermes in 2003, prior to which he managed EMD Serono’s North America financial operations. Mr. Brown received a Bachelor of Science in Business Studies from the University of Bradford, England and is a Chartered Accountant.
Madeline Coffin leads Alkermes’ human resources team, with responsibility for global compensation and benefits, talent acquisition, employee engagement and growth and organization development. Ms. Coffin has held a number of senior human resource positions at companies including Analog Devices, Sun Microsystems, Wang Software and Bay Networks. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients in a broad range of industries. Ms. Coffin holds a Bachelor of Arts degree from Penn State University and a Master of Industrial and Labor Relations from Cornell University.
Elliot Ehrich leads the discovery, delivery science, research and development, project management and medical affairs functions at Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., overseeing the successful clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. He also serves on the Scientific Advisory Boards of Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies, as well as a Strategic Advisor at Verge Genomics. Dr. Ehrich was a Phi Beta Kappa graduate of Princeton University where he received a Bachelor of Arts degree in biochemistry. He worked as a research associate at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and later earned his medical degree from Columbia University, College of Physicians and Surgeons. At Stanford University, Dr. Ehrich completed a residency in internal medicine and a clinical fellowship in the Department of Immunology and Rheumatology. He was subsequently a postdoctoral research fellow at the Howard Hughes Medical Institute at Stanford University School of Medicine, in the Department of Microbiology and Immunology.
Jim Frates serves as Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Mr. Frates was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Mr. Frates served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. Mr. Frates serves on the Board of Directors of SAGE Therapeutics and as a Trustee of St. Paul’s School and the Roxbury Latin School. Mr. Frates received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.
David Gaffin serves as Alkermes’ in-house Chief Legal Officer, managing the operations of the legal department. Mr. Gaffin was most recently the U.S. General Counsel of Alkermes. Prior to joining the company in 2005, Mr. Gaffin held the role of Assistant General Counsel at Biogen Inc., where he provided legal counsel on product-related matters and negotiated collaboration and licensing transactions. Mr. Gaffin received a Bachelor of Arts degree from Harvard College, a Master of Business Administration from J.L. Kellogg Graduate School of Management and a Juris Doctor from Northwestern University School of Law.
Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.
Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson serves on the Board of Directors of Reset Therapeutics, Inc. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.
Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.
Mark Namchuk leads research, pharmaceutical development, process development and nonclinical development of the company’s early-stage product pipeline at Alkermes. Prior to joining Alkermes in 2015, Dr. Namchuk served as Senior Vice President and Interim Global Head of Research for Vertex Pharmaceuticals, leading a group of more than 450 researchers in the discovery of transformational medicines in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. In addition, Dr. Namchuk developed the high throughput enzymology paradigm in support of the Vertex Chemogenomics effort and co-chaired the committee responsible for new-target selection and prosecution for the company. Earlier in his career, he served as the head of the biochemistry group at Cubist Pharmaceuticals. Dr. Namchuk obtained his doctorate in bioorganic chemistry from the University of British Columbia and completed a post-doctoral fellowship at the University of California, San Francisco.
Peter Norman leads the U.S. Government Affairs and Policy function for the company, which includes federal and state initiatives as well as programs with professional and patient organizations. Prior to joining Alkermes in 2013, Mr. Norman was the head of the Washington, D.C. office for Eisai, Inc. In addition, he’s held senior positions for Amylin Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novo Nordisk and the Biotechnology Industry Organization (BIO). Mr. Norman worked on public policy and regulatory strategies not only for Alzheimer’s disease, obesity and diabetes pharmaceutical products, but also healthcare reform and reimbursement issues. He received a Bachelor of Arts degree from Adrian College and a Juris Doctor from the University of Toledo College of Law.
Declan O’Connor is responsible for Alkermes’ manufacturing operations at the Athlone, Ireland and Wilmington, Ohio sites as well as its commercial and clinical supply chain functions. Mr. O’Connor is responsible for the strategic development of operations activities and site infrastructure development. He joined Alkermes as Vice President and General Manager in Athlone upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. In this role, he was responsible for the company’s FDA/EMA licensed multi-product development, manufacturing and packaging operations in Ireland. Mr. O’Connor held a number of senior operations positions for Elan including Vice President of Finance, Head of Global Supply Chain and Head of Finance U.S. Operations. Mr. O’Connor is a chartered accountant and a graduate of University College Dublin, Ireland.
Phil Shanahan is responsible for quality control, quality assurance and compliance at the Athlone, Ireland and Wilmington, Ohio sites, and the quality assurance function at the Waltham site. Dr. Shanahan joined Alkermes as Vice President, Quality Operations upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Dr. Shanahan has more than 15 years of experience in quality operations. Prior to joining Elan, he served at Servier and Janssen Global Services, LLC. Dr. Shanahan obtained his doctorate in analytical biotechnology and his Bachelor of Science in chemistry from University College Cork. He holds a diploma in pharmaceutical manufacturing technology and is a certified Qualified Person (QP) for the release of product to the European Union.
Mark Stejbach serves as Chief Commercial Officer at Alkermes and is responsible for all aspects of Alkermes’ commercial functions, including sales, marketing, managed care and trade channels, commercial analytics, public policy and the development of commercial strategy for the company’s proprietary pipeline. Mr. Stejbach has more than 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Prior to joining Alkermes, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. He currently serves on the Board of Directors of Flexion Therapeutics. Mr. Stejbach received his MBA from The Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.